


LEQVIO® DEMONSTRATED CONSISTENT REDUCTION ACROSS PREDEFINED SUBGROUPS⁶

Percent change in LDL-C from baseline at month 17 in a pooled analysis of Phase III trials^{5,6}



^aPatients with a history of a statin intolerance.
^bFactors that increase risk of CVD include HeFH, T2DM, or 10-year risk of ≥20%.²